Pharmacy led medicine reconciliation at hospital: a systematic review of effects and costs by Hammad, Eman A. et al.
Accepted Manuscript
Pharmacy led medicine reconciliation at hospital: a systematic review of effects and
costs
Eman A. Hammad, PhD, Amanda Bale, BA, David J. Wright, PhD, Debi Bhattacharya,
PhD
PII: S1551-7411(16)30020-1
DOI: 10.1016/j.sapharm.2016.04.007
Reference: RSAP 737
To appear in: Research in Social & Administrative Pharmacy
Received Date: 20 December 2015
Revised Date: 29 April 2016
Accepted Date: 29 April 2016
Please cite this article as: Hammad EA, Bale A, Wright DJ, Bhattacharya D, Pharmacy led medicine
reconciliation at hospital: a systematic review of effects and costs, Research in Social & Administrative
Pharmacy (2016), doi: 10.1016/j.sapharm.2016.04.007.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
Pharmacy led medicine reconciliation at hospital: a systematic review of 
effects and costs  
 
Eman A Hammad, PhD1, Amanda Bale, BA2, David J Wright, PhD 3, Debi 
Bhattacharya, PhD3 
1. School of Pharmacy, Department of Biopharmaceutics and Clinical Pharmacy, University 
of Jordan, Jordan 
2. Pharmacy Department, Cambridge University Hospitals, Cambridge, UK 
3. School of Pharmacy, University of East Anglia, UK 
 
Correspondence and reprint requests addressed please to: Dr Eman Hammad, Department of 
Biopharmaceutics and Clinical Pharmacy, School of Pharmacy, University of Jordan, 
Amman 11942, Email: e.hammad@ju.edu.jo, Telephone: +962 (0) 778255469, Fax: Fax: 
+9626-5300250 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
1 
 
Abstract  1 
Background: Transition of patients care between settings presents an increased opportunity 2 
for errors and preventable morbidity. A number of studies outlined that pharmacy-led 3 
medication reconciliation (MR) might facilitate safer information transfer and medication 4 
use. MR practice is not well standardised and often delivered in combination with other 5 
healthcare activities. The question regarding the effects and costs of pharmacy-led MR 6 
and the optimum MR practice is warranted of value. Objectives: To review the evidence 7 
for the effects and costs/ cost-effectiveness of complete pharmacy-led MR in hospital 8 
settings. Methods: A systematic review searching the following database was conducted up 9 
to the 13th December 2015; EMBASE & MEDLINE Ovid, CINAHL and the Cochrane 10 
library. Studies evaluating pharmacy-led MR performed fully from admission till discharges 11 
were included. Studies evaluated non-pharmacy-led MR at only one end of patient care or 12 
transfer were not included. Articles were screened and extracted independently by two 13 
investigators. Studies were divided into those in which: MR was the primary element 14 
of the intervention and labelled as “primarily MR” studies, or MR combined with non-15 
MR care activities and labelled as “supplemented MR” studies. Quality assessment 16 
of studies was performed by independent reviewers using a pre-defined and 17 
validated tool. Results: The literature search identified 4,065 citations, of which 13 18 
implemented complete MR. The lack of evidence precluded addressing the effects and costs 19 
of MR. Conclusions: The composite of optimum MR practice is not widely standardised and 20 
requires discussion among health professions and key organisations. Research focused on 21 
evaluating cost-effectiveness of pharmacy-led MR is lacking.   22 
  23 
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Keywords: Medicine/ medication reconciliation, care transition errors, costs, hospital 24 
pharmacy, pharmacy-led medicine reconciliation 25 
 26 
Abbreviation:  27 
MR: medicine reconciliation   28 
  29 
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Introduction  30 
Transition of patient care between settings presents an increased opportunity for 31 
error. Poor communication of clinical information at healthcare transitions is 32 
responsible for over 50% of all medication errors and up to 20% of adverse events.1-4 33 
At least half of discrepancies at discharge originate from discrepancies in medication 34 
histories, and 72% of all potentially harmful discrepancies in admission or discharge 35 
orders were due to errors related to compiling pre-admission medicines list.5, 6.It is 36 
also estimated that 12% of adverse drug events upon hospital admission were 37 
related to medicine use and that each adverse event increase hospital stay by 8.5 38 
days on average..3,7  39 
Medicine reconciliation (MR) is proposed as a solution for communication deficits 40 
between healthcare settings.2, 8, 9,10 In the US, the Joint Commission for health care 41 
organizations accreditation defines MR as the process of “obtaining and maintaining 42 
an accurate, detailed list of all medicines taken by a patient and using this list to 43 
provide correct medicines anywhere within the health care system”.10 In the UK, MR is 44 
described similarly and recommended to be performed every time a transfer of care takes 45 
place.11 46 
Studies have outlined that MR facilitates safer medication use after patient transfer 47 
of care.12-18 Of note, two systematic reviews of hospital-based MR, Kwan et al.,17and 48 
Mueller et al.,18 supported MR interventions that relied on pharmacists to improve the 49 
transfer of medication information. It was highlighted also that MR when bundled with 50 
other healthcare activities such as medication review and discharge planning might 51 
improve clinical and healthcare utilisation post discharge. 17 However, the cost/cost-52 
effectiveness of MR was not fully addressed, and MR was not always fully 53 
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implemented. Thus little was concluded whether the observed beneficial effects may 54 
justify costs and what would be the composites of optimised MR practice. 55 
The Institute of Healthcare Improvement stated that occasionally MR is not fully 56 
implemented. For some organisations, MR is widely accepted as a medication 57 
history-taking task, and in others it includes only discharge reconciliation. 19 MR 58 
continues to be a challenge for many hospitals and care settings. This is due to the 59 
lack of clear ownership of MR and the need for developing a standardised approach 60 
to implement MR. 19 Thus, exploring the existing evidence to identify the features of 61 
MR practice and the resources necessary to deliver is warranted.  62 
This systematic review aimed to synthesise evidence to determine the effects and 63 
costs associated with complete MR; in which MR is implemented at admission and 64 
continued through the hospital stay until discharge and where patient information is 65 
fully and accurately communicated to the next health provider. This would enable 66 
service purchasers and health policymakers to make more informed decisions 67 
regarding MR optimum practice and cost implications. 68 
Methods 69 
Identification of studies  70 
PRISMA guidelines were used to inform this systematic review. A literature search 71 
was carried out from the start date of the database (noted in parentheses) to the 72 
13th December 2015. The following databases were reviewed; EMBASE (1946) & 73 
MEDLINE Ovid (1950), CINAHL (1961) and the Cochrane library including Cochrane 74 
Database of Systematic Review (1988), Database of Abstracts of Reviews of Effects 75 
and the NHS Economic Evaluation Database (1991), the Centre of Reviews and 76 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
Dissemination and PHARMLINE provided by the National electronic Library for 77 
Medicines (1970).  78 
Search terms were set by the authors prior to the beginning of the electronic search. 79 
Scoping searches reviewing published MR articles and citation searches using the 80 
SCOPUS database were conducted to identify all relevant search terms. Search 81 
terms were discussed with peer researchers with mixed professional and research 82 
backgrounds in an open forum. Search terms were revised accordingly. 83 
Bibliographies and reference lists of the identified studies and systematic reviews 84 
were revised to identify additional relevant articles. Authors and key institutions 85 
including the UK National Patient Safety Agency and National Prescribing Centre, 86 
Institute of healthcare improvement, the Agency of Healthcare research and Quality 87 
and Joint Commission in the US were contacted by email to obtain any relevant 88 
work. Search terms included: medicine/medication reconciliation, medical record 89 
review or assessment, drug history-taking, seamless care plus information 90 
communication and care transfer. Truncations (*), wild cards ($), hyphens and other 91 
relevant Boolean operators were used where permitted. The search strategy 92 
(Appendix 1) is available upon request. No restriction on language or publication 93 
date was applied. Non-English studies were translated to English language by an 94 
independent researcher who speaks fluently in several languages.   95 
Inclusion and exclusions criteria  96 
Eligible studies were those evaluating adults and children receiving pharmacy-led 97 
MR within hospital inpatient settings. All types of admissions and ward specialities 98 
were considered. Only studies describing clearly that MR was implemented fully 99 
upon admission through the hospital stay until discharge and with patient information 100 
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being communicated accurately to the next health provider were included. The term 101 
‘complete MR’ was used for this review. Studies evaluating non- pharmacy-led MR at 102 
only one end of patient care or transfer were not included. Studies evaluating pharmacy-103 
led MR using a qualitative approach and studies evaluating enhanced interventions, 104 
including telephone helpline and post discharge follow-up calls, were excluded. 105 
Telephone helpline and follow-up calls were not considered part of MR and 106 
suspected to influence readmissions and healthcare utilisation.20, 21 Thus; these were 107 
excluded to avoid bias in favour of the intervention. 108 
Study selection and Data extraction  109 
Screening of titles and abstracts for relevance and data extraction was performed 110 
independently by two authors; EH and AB. Discrepancies were discussed to obtain 111 
consensus, disagreement was resolved by a third author (DB).   112 
Abstracted data were related to study design, authors, country of correspondence, 113 
year of publication and setting, study population, number of participants, 114 
demographics and baseline comparability if applicable. Details of the study 115 
intervention, including who and when implemented MR and what comprised the MR 116 
service, and the standard care in the study site, were extracted. Studies evaluating 117 
complete MR performed by pharmacy staff in a hospital setting were relevant to the 118 
review. Non-pharmacy-led MR was considered out of the scope of this review. 119 
Studies were divided into two subsets: those in which MR was the primary element 120 
of the intervention and labelled as “primarily MR” studies, and studies in which the 121 
MR intervention was performed in bundle with other non-MR healthcare activities. 122 
The latter were labelled as “supplemented MR” studies. This classification was to 123 
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enable better understanding of the dynamic of MR practice and the true impact of 124 
MR on patient outcomes and health costs. 125 
Outcomes and cost estimation 126 
Details related to the effect of MR were recorded as process-oriented outcomes such 127 
as medication discrepancy rate, clinical significance of medication discrepancy and 128 
resources necessary to implement MR including time and training. Patient-oriented 129 
outcomes included health resource use in hospital and community, health related 130 
quality of life and mortality rate. 131 
Costs related to the extra time commitment needed to implement MR and savings 132 
due to reductions in medicines taken during the hospital stay were extracted. Cost 133 
savings related to hospital and emergency department revisits, health resource use 134 
in community and the time of doctors and nurses freed from obtaining accurate 135 
medication histories and transcribing medications changes were extracted.  136 
High heterogeneity due to disparate study designs and measured of outcomes 137 
deemed meta-analytic data reporting inappropriate. However, where a common unit 138 
of outcome measure we reported the effect and/or costs was pooled. The central 139 
tendency and range/SD were estimated using Microsoft Excel (Microsoft, Seattle, 140 
Washington). This approach has been used in similar systematic reviews.17, 22 141 
Cost estimation 142 
Pooled outcomes were valued in monetrary units using the unit costs reported by personal 143 
social services research units and Department of Health reference costs in UK for the 144 
financial year 2012/2013, avalible at: www.pssru.ac.uk/. The average cost per patient was 145 
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calculated for each pooled outcome by multiplying the pooled health resouce 146 
consumed/saved by the relevant average unit cost.  147 
Assessing risk of bias 148 
Two of the investigators independently assessed risk of bias using a tool based on 149 
the Cochrane Collaboration risk of bias tool for randomised controlled studies. 23 In 150 
addition to the Cochrane risk domains for randomised controlled studies, the 151 
following risk domains were assessed: design, baseline comparability, standardised 152 
intervention delivery and outcome measurement and sample size calculation. These 153 
domains were to enable more comprehensive evaluation for the quality of non-154 
randomised and uncontrolled studies. The tool was piloted and validated to fit the 155 
purpose of this review (Appendix 2); it was presented to researchers with systemic 156 
review experience from different disciplines. They were invited independently to 157 
assess the quality of two articles using the tool and provide interactive feedback via 158 
group and one to one discussions. Disagreements were referred and resolved by a 159 
third reviewer (DB).  160 
This review registration number at the international prospective register of systematic 161 
reviews (PROSPERO) is CRD42012002386.  162 
  163 
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Results  164 
The literature search identified 4,065 citations, of which 13 met the inclusion criteria. 165 
The study selection process and number of papers excluded at each stage of the 166 
review are summarised in Figure 1. Studies were most frequently excluded because 167 
they were not pharmacy-led and were not evaluating complete MR. Box 1 highlights 168 
the composite of MR practices across a selection of excluded articles. 169 
The majority of studies were conducted in Europe of which three were in Northern 170 
Ireland.24-26 Five studies were based in the USA and Canada 27-31 and one study in 171 
Australia.32 One study was reported in French 33 and the remainder were in English. 172 
Table 1 summarises the characteristics of included studies with respect to study 173 
design. There were seven controlled studies 24, 26-29, 32,34 of which three were 174 
randomised, 26, 27, 30, 32 one non-randomised prospective observational 24 and three 175 
before and after study designs.28, 31, 34 The remaining were prospective uncontrolled 176 
studies.25, 29, 33, 35, 36 A detailed description of comparators and the study inclusion 177 
criteria are also presented in Table 1. It can be seen that what constituted a standard 178 
care varied across the reviewed studies.  179 
  180 
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 181 
a Full text was revised to enable decisions for exclusion, incase of uncertainty authors were contacted.. b e.g. 182 
follow up phone call and medicine help line. b Authors were contacted; no published or unpublished relevant data 183 
were available.  184 
 185 
Figure 1. Study selection and reasons for exclusion186 
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Table 1. Summary of included studies 
Authors, Year Study design (sample size) Control  Inclusion criteria  
Andregg, 2014 31 Before and after 
Pre-implementation (n=1664) 
Post-implementation (n=1652) 
Standard care included MR upon 
admission only to all patient  
Age:≥18years 
Condition: discharged from 
internal medicine, family medicine, cardiology, or 
orthopaedic surgery 
medical services 
Brookes, 2000 25 Prospective uncontrolled 
(n=109) 
- Age:≥60 years 
Number of medications:≥4 medicines 
Others: Admitted via the medical admission unit 
Hellstrom, 2011 34 Before and after  
Pre-implementation (n=101) 
Post-implementation (n=109) 
Standard care included only MR upon 
discharge 
Age:≥ 65 years 
Number of medications:≥one medicines for regular use 
Hick, 2001 24 Prospective controlled (n=50) 
in each group 
Standard post-admission pharmacist 
ward visit involving checking and 
resolving medication chart errors and 
omissions 
Age:≥ 29 years 
  187 
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Continued 
Table 1 Summary of included studies 
Authors, Year Study design (sample size) Control  Inclusion criteria  
Israel, 2013 30 Randomised controlled study 
Standard care (n=246) 
Minimal intervention (n=245) 
Enhanced intervention (n=241) 
  
Usual care included no medication 
education but did receive a discharge 
medication list and oral information from a 
hospital unit nurse. 
Age:≥18 years 
Condition: admitted with a diagnosis of hypertension, 
hyperlipidemia, heart failure, coronary artery disease, myocardial 
infarction, stroke, transient ischemic attack, asthma, chronic 
obstructive pulmonary disease, or diabetes or were receiving oral 
anticoagulation.  
Others: admitted to the internal medicine, family medicine, 
cardiology, or orthopaedics service and receive their usual medical 
care in the community and their prescriptions from a community 
pharmacy. 
Kramer, 2007 28 Before and after study  
Pre-implementation (n=147) 
Post-implementation (n=136) 
Pre-implementation phase included 
admission medication histories and 
discharge medication counselling 
followed standard care process which 
included a nurse-led MR 
Age:≥18years 
Makowsky, 2009 27 Multi-centre, quasi controlled 
clinical trial 
Intervention (n=220) 
Control (n=231) 
Usual care included traditional reactive 
clinical pharmacy by either ward-based 
or dispensary-based staff pharmacists 
Age:>18 years  
Condition: Primary diagnosis of coronary artery disease, community 
acquired pneumonia, chronic obstructive pulmonary disease, heart 
failure, or type 2 diabetes mellitus and not due palliative cancer 
Perennes, 2012 33 Prospective uncontrolled (n=61) - Age: ≥65 years old or more. 
  188 
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Continued 
Table 1. Summary of included studies 
Authors, Year Study design (sample size) Control  Inclusion criteria  
Rabi and Dahdal, 
2007 36 
Prospective uncontrolled (n=150) - All patients offered intervention 
Scullin, 2007 26 Randomised controlled study 
Intervention (n=371) 
Control (n=391) 
Usual care Age:≥65 years 
Number of medications: ≥four regular medications, 
taking a high risk medicine(s) or anti-depressant 
Others: A previous hospital admission within the last 
six months, prescribed intravenous antibiotics on the 
day of admission 
Stowasser, 2002 32 Randomised controlled study 
Intervention (n=104) 
Control (n=105) 
Usual care by a clinical pharmacist 
included review of medication history and 
current medication, medication supply, 
counselling on medications and preparing 
discharge medicines 
Patients returning to community following discharge 
Vira, 2006 29 Prospective uncontrolled 
(n=60) 
Usual care included Pharmacist or nurse 
verification of the patients’ medication 
history only if requested by the physician 
or evidence of incomplete or unusual drug 
orders. At discharge, pharmacists 
provided medication education if 
requested by a physician and for 
additional patients as time permitted 
All new admission in the previous 24 hours 
  189 
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Table 2 summarises the composite of the reviewed interventions. Four studies were 190 
primarily MR. 28, 29, 33, 36 The remainder were supplemented MR. MR was often 191 
bundled with pharmacotherapy consultation or medication review, patient 192 
consultation and discharge planning. Patients were very similar in terms of 193 
demographic characteristics. Average age ranged between 55 and 93 years and 194 
equal male to female ratio. Patients were prescribed a mean (SD) of 7 (4.3) 195 
medicines. Characteristics of included patients are summarised in Box 2. 196 
Quality of the evidence  197 
Outcomes of bias assessment by study and type of bias are presented in Figures 2 198 
and 3, respectively. Studies were considered at high risk for design bias particularly 199 
randomisation and allocation concealment. Risk of bias in terms of selection was 200 
often low, specifically in relation to baseline comparability and patient selection (10 201 
out of 13). Performance bias with respect to delivery of the intervention and outcome 202 
measurements was generally low (9 out of 13). Detection bias was low for five 203 
studies, 25-27, 32, 34 and most studies were considered not susceptible to selective 204 
reporting (11 out of 13). Only five studies introduced no concerns regarding the 205 
adequacy of the study power and the statistical analysis.26, 27, 30, 34, 35   206 
 207 
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Table 2 Components of pharmacy-led MR by study 208 
Study  All MR 
elements  
Pharmacotherapy 
consultation & 
medication review 
Discharge 
counselling/planning 
Patient and 
carer 
education  
Written medication 
information handed 
to patient 
Ward round 
and bedside 
care 
Medication 
supply/patient own 
drugs management 
Andregg, 2014** 
31
 
       
Brookes 
2000**25 
       
Hellstrom 
2011**34 
       
Hick 2001**24        
Israel, 2013**30        
Karapinar-Carkit 
2012**35 
       
Kramer 2007*28        
Makowsky 
2009**27 
       
Perennes 
2012*33 
       
Rabi and 
Dahdal. 2007*36 
       
Scullin 2007**26        
Stowasser 
2002**32 
       
Vira 2006*29 
       
Frequency 13 8 8 5 4 2 2 
*Primarily MR studies; i.e. MR the primary element of the intervention. ** Supplemented MR studies; i.e. MR supplemented often with pharmacotherapy consultation or medication review, 209 
patient consultation and discharge planning  210 
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Figure 2 Risk of bias assessment by study Low risk of bias High risk of bias Risk of bias 213 
unclear214 
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 215 
Figure 3 Outcomes of bias assessment by type of bias  216 
 217 
  218 
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Effects of pharmacy-led MR 219 
Table 3 summarises the effect of MR on process and patient-oriented outcomes. The 220 
mean number of discrepancies reported per patient varied considerably between 221 
studies ranging from 0.35 to 4.85. 28, 36,33,29, 24, 35,26,32, 27 Supplemented MR studies 222 
appeared to report more often a positive impact, particularly on readmission rate and 223 
length of hospital stay, compared to primarily MR studies. At 30 days, the pooled 224 
median (range) reduction in readmission and emergency department visits was 4% 225 
(1%, 5.9%).28, 32, 31, 35 Anderegg et al.31 reported a significant reduction in 30-day 226 
readmission rate for patients with high risk; 5.5% (p=0.042). Those were patients 227 
hospitalized with acute myocardial infarction, congestive heart failure or pneumonia 228 
and chronic obstructive pulmonary disease and on oral anticoagulation. At three 229 
months, the reduction in readmission and emergency department visits ranged from 230 
6.4% to 9.3%.27, 34 This effect was statistically significant (p= 0.045 and 0.047, 231 
respectively). However, the effect was not significant at six months post discharge.27 232 
At twelve months post discharge, Scullin et al. found a significant reduction 233 
readmissions rate in the intervention group compared to the control group. Patients 234 
also took longer time to be readmitted; 262 days and 242 days, respectively.21  235 
There was a mixed effect of MR on hospital stay with a pooled median (IQ) increase 236 
in hospital stay of 8.4 (0, 16) hours 26-29, 31-35 for the intervention. Makowsky et al.27 237 
reported that patients in the intervention group stayed longer in the hospital. The 238 
adjusted median ratio of hospital stay [95% CI] was 1.16 [1.01, 1.34] (p=0.031).27 In 239 
contrast, Scullin et al. reported two days reduction in hospital stay with patients in the 240 
intervention group (p=0.003).26  241 
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Health resource use in community and heath related quality of life were evaluated by 242 
only one Australian study using a postal survey 30 days post discharge.32 The total 243 
number of health visits and resource use post discharge was significantly lower in 244 
the intervention group. Mortality at 12 months was assessed by three studies, none 245 
identified a significant impact.26, 32,34  246 
 
247 
 248 
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Table3 Summary of MR effects on process and patient oriented outcomes  
Intervention 
type 
Study Process oriented outcomes   Patient oriented outcomes 
Overall 
discrepancies 
(per patient) 
Clinically 
significant 
unintentional 
discrepancies 
(per patient) 
Readmission and 
emergency visit 
rate 
Average hospital 
stay 
 
Health resource use Quality of life Mortality
 Kramer, 2007 28 0.35 -  No change - - - 
 
Rabi and 
Dahdal,2007 36 1 - - - - - - 
Primarily MR Perennes, 2012 33 0.62 0.033 - 
 
- - - 
 Vira, 2006 29 2.3 0.33 - 
 
- - - 
 
Anderegg, 2014 
31
 
- -  
 
?? - - 
 Brookes, 2002 25 - - 
 
- - - - 
 
Hellstrom, 2011 
34
 
- - 
  
- - 
 
 Hick,2001 24 2.48 - 
-  
- - - - 
 Isreal, 2013 30 - - - - - - - 
Supplemented 
MR 
Karapinar-Carkit, 
2012 35 2.98 - -  - - - 
Makwosky, 2009 
27
 
4.85 -  
 
- - - 
Scullin, 2007 26 5.5 -   - -  
 
Stowasser , 2002 
32
 
0.77 - 
     
: not statistically significant  : statistically significant. ??: the author reported no direction of change but stated this to be overall statistically 249 
nonsignificant.  250 
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Costs and savings associated with Pharmacy-led MR 251 
Time spent by pharmacists to implement complete MR was estimated in six studies; the 252 
pooled median (IQ) time was 50 (14, 50) minutes.24, 28, 29, 33, 35,36 Details of the time spent 253 
in each study are shown in Box 3.  254 
None of the included studies incorporated a full economic evaluation of the cost and/or 255 
cost-effectiveness of MR. Karapinar-Carkit et al.35 performed a cost analysis from a 256 
health insurer’s perspective. MR was performed by a team of pharmaceutical 257 
consultants who were pharmacy technicians completed an additional three-year degree 258 
and obtained further pharmacotherapy and patient communication training. Savings in 259 
medicine costs were €21.77/patient (USD $24.79) at one month and €96.65/patient 260 
(USD $110.07) at six months. The savings did not outweigh the pharmacy consultant’s 261 
labour cost after one month, but did outweigh the labour costs at six months post 262 
discharge with a net saving of €55.62 /patient (USD $63.34) (sensitivity analysis €37.25-263 
€71.10; USD $42.42- 80.97). Saving was estimated if MR was provided by a clinical 264 
pharmacist or a pharmacy technician. Net savings were €47.41/patient (USD $53.99) 265 
(€25.37-€65.98; US$ 28.89-75.14) with the clinical pharmacist, and €63.82/patient (USD 266 
$72.68) (€49.13-€76.21; USD $55.95-86.79) with the pharmacy technician.  267 
Cost savings related to reconciliation of the patient’s own drugs upon admission were 268 
evaluated by Brookes et al.25 The extra prescription costs that would have been saved if 269 
home medications of 13 patients were reconciled and taken during hospital stay was on 270 
average £25.22 (USD $35.93). Annually, this would translate to £15,000 (USD 271 
$21,367).  272 
Cost savings related to prevention of readmissions and hospital stay was outlined in 273 
three studies. Brookes et al.25 estimated that eighteen readmissions were prevented 274 
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and extrapolated this to 72 readmissions with average stay of 7.7 days. Consequently, 275 
total cost savings was estimated as £80,000 (USD $113,958) annually. Andereeg et 276 
al.31 estimated that the pharmacy team interventions could prevent approximately 75 277 
readmissions of high-risk patients per year. At an average direct cost of USD $10,446 278 
per readmission including the cost for medications, laboratory testing, imaging, and 279 
other resource charges, the potential annual cost savings would be USD $783,450. 280 
With overhead expenses, the annual estimated saving were estimated as USD 281 
$1,121,850. Scullin et al. estimated over £3 million (USD $4,273,41) annual savings due 282 
to reductions in hospital stay. 26 283 
Two studies estimated savings related to the time of other members of the healthcare 284 
team.24, 28 The time spared for doctors and nurses was 14 minutes per patient 24 and 285 
one hour, respectively.28 However, this was not valuated in monetary units.  286 
Cost estimation 287 
The valuation of doctor and nurse time using the reference unit cost reported by the 288 
Personal and Social Services Research Unit in the UK for the year 2012/2013, 289 
estimates savings of £85 (USD $121.08) per patient in nurse time and £8.75 (USD 290 
$12.46) per patient for doctor time. The average cost of pharmacist time to implement 291 
MR would be £14.7(USD $20.93) (£13.8-£49.2; USD $19.65- USD $70.08) per patient. 292 
The average costs of excess hospital stay can be estimated as £92.4 (USD $131.62) 293 
(£0-£176; USD $0-$250.70). Savings in terms of preventing readmissions at 30 days 294 
post discharge can be estimated at £5,744 (USD $8,182) (£2,872-£8,472; USD $4,091- 295 
$12,068). At three months, savings can be estimated as £1,344 (US$ 1,914) (£9,190-296 
£13,354; US$ 13,090- US$19,022).  297 
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Discussion  300 
MR is a well-defined process and recommended to take place each time the patient is 301 
transferred between health settings or different levels of care within the same 302 
setting.1,2,4, 10, 11,19 However, MR is prioritised and delivered differently across countries 303 
and health organizations.10,11,19 Thus, the composite of the optimum practice of MR is 304 
not widely standardised and requires further discussion among health professions and 305 
organizations. The current review identified only a limited number of studies; 13 306 
implemented MR fully from admission until discharge and communicated updated 307 
information to the next health provider. In some institutions and healthcare systems, MR 308 
is delivered at admission namely through medication history-taking, or simply at 309 
discharge alone or bundled with more specialised service such as medication 310 
review.37,38 MR provided at one end of patient care or transfer was considered 311 
incomplete in this review.  312 
Additionally, MR is often bundled with pharmacotherapy consultation and reviews ,25-313 
27,30,35,36
 and discharge counselling.25,27,28,30,31,35,33,36 MR appears to be a 314 
multidisciplinary and multidimensional health process; i.e. it requires collaboration of 315 
various health providers at various care levels. Thus, MR can be integrated with a 316 
multicomponent care bundle designed to improve patient outcomes. Hence, the 317 
relevance of assessing MR effects in isolation of other care activities might be 318 
questionable in some contexts, and implementation of MR fully faces number of 319 
challenges. This has been highlighted in a number of professional and health 320 
management meetings.39,19 Therefore, developing a well-defined MR process and highlighting 321 
the role of pharmacists in optimising the delivery and application of MR are needed. Further 322 
research and discussion among healthcare systems and world organisations to encourage 323 
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organisations to define their own MR process and adopt MR within their routine workflows is 324 
warranted.  325 
This review highlighted that continuity of care was improved by MR pharmacist 326 
intercepting and clarifying medication discrepancies.28,29,33,36 However, these 327 
discrepancies were not always considered clinically significant, and thus little can be 328 
said as to whether intercepting MR discrepancies precludes actual patient harm. This 329 
corroborates previous MR reviews requesting future studies to focus on evaluating 330 
actual harm and patient-oriented outcomes.17, 18, 40  331 
Kwan et al.,17 suggested that MR alone probably does not reduce post discharge hospital 332 
utilisation but may do so when bundled with interventions aimed at improving care transitions. 333 
This review found the evidence is lacking and was of poor quality, precluding confirmative 334 
conclusions for the effects of MR alone or when bundled with other care activities. Without 335 
detailed investigation of the nature of each unit of resource used, it is not possible to draw 336 
definitive conclusions. Thus, the effects on readmissions, length of hospital stay, post discharge 337 
health resource use, mortality and quality of life will remain uncertain unless these details were 338 
collected compressively.  339 
Strengths and limitations  340 
There is no other comprehensive review that scoped effects and costs of implementing full MR 341 
and highlighted the features of MR practice in the context of non-MR healthcare activities. The 342 
empirical valuation for the costs of MR was useful to highlight the potential cost drivers and data 343 
needed to conduct useful cost/ cost-effectiveness evaluation in future. This review implemented 344 
a comprehensive search strategy by independent reviewers. All key terms systematically were 345 
searched through all relevant databases, key authors and institutions with no limitations to study 346 
language, year of publication or design. No other MR review implemented a comprehensive 347 
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quality assessment that enable the reader to understand the quality of each study and weighted 348 
them differently based on the robustness of their findings. 349 
However, this systematic review is subject to a number of limitations. The reviewed studies were 350 
limited and of inadequate quality. They were mainly non-randomised and/or uncontrolled 351 
designs. Additionally, the composite of the reviewed interventions varied widely and represented 352 
very heterogynous MR practice. Thus, the generalizability of this review must be considered in 353 
light of the differences existing between worldwide health care systems, processes for sharing 354 
information, and funding of patient care.41.  355 
Conclusion 356 
This review provided an empirical valuation of MR costs and highlighted that the extra 357 
time commitment to implement MR and details of post discharge resource use are potentially 358 
the main cost drivers to inform policy makers as to the cost implications of MR. Research 359 
focused on evaluating cost-effectiveness of pharmacy-led MR should be a priority 360 
because evidence is scant.  Providing a comprehensive pharmacy-led MR service to patients 361 
may be desirable; however, it is essential to identify the situations most likely to benefit from 362 
pharmacy-led MR and to target areas where MR impact is maximised.   363 
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Appendix 1. Example of search strategy applied in EMBASE and MEDLINE Ovid 483 
database in 23.11.2012 484 
 
 
Search terms 
1. medicine$.ti,ab. 
2. Medication$.ti,ab. 
3. drug$.ti,ab. 
4. 
medicament$.ti,ab  
5. prescription$.ti,ab.  
6. (medic$ adj2 chart$).ti,ab.  
7. (medic$ adj2 record$).ti,ab.  
8. 1 or 2 or 3 or 4 or 5 or 6 or 7 
9. ((medicine$ or medication$ or drug$ or medicament$ or prescription$ or 
(medic$ adj2 chart$) or (medic$ adj2 record$)) adj2 reconciliation).ti,ab.  
10. ((medicine$ or medication$ or drug$ or medicament$ or prescription$ or 
(medic$ adj2 chart$) or (medic$ adj2 record$)) adj2 management).ti,ab.  
11. ((medicine$ or medication$ or drug$ or medicament$ or prescription$ or 
(medic$ adj2 chart$) or (medic$ adj2 record$)) adj2 assessment).ti,ab.  
 
12.  ((medicine$ or medication$ or drug$ or medicament$ or prescription$ or 
(medic$ adj2 chart$) or (medic$ adj2 record$)) adj2 review$).ti,ab.  
13. ((medicine$ or medication$ or drug$ or medicament$ or prescription$ or 
(medic$ adj2 chart$) or (medic$ adj2 record$)) adj2 histor$).ti,ab.  
14. information.ti,ab.  
15. (information adj2 transfer$).ti,ab.  
16. information adj2 continu$).ti,ab.  
17. ((medicine$ or medication$ or drug$ or medicament$ or prescription$ or 
(medic$ adj2 chart$) or (medic$ adj2 record$)) adj2 system$).ti,ab.  
18 ((medicine$ or medication$ or drug$ or medicament$ or prescription$ or 
(medic$ adj2 chart$) or (medic$ adj2 record$)) adj2 congruence$).ti,ab. 
19 ((medicine$ or medication$ or drug$ or medicament$ or prescription$ or 
(medic$ adj2 chart$) or (medic$ adj2 record$)) adj2 communication).ti,ab.  
20 (information adj2 communication).ti,ab.  
21 ((medicine$ or medication$ or drug$ or medicament$ or prescription$ or 
(medic$ adj2 chart$) or (medic$ adj2 record$)) adj2 liaison).ti,ab.  
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22 
care.ti,ab.  
23 (seamless adj2 care).ti,ab.  
24 discrepanc$.ti,ab.  
25 Error$.ti,ab.  
26 transition$.ti,ab.  
27 9 or 10 or 11 or 12 or 13 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 23 or 25 
or 26  
28 Secondary adj1 care).ti,ab.  
29 hospital$.ti,ab.  
30 inpatient$.ti,ab.  
31 interface$.ti,ab.  
32 dicharge$.ti,ab.  
33 
admission$.ti,ab.  
34 28 or 29 or 30 or 31 or 32 or 33  
35 pharmacist$.ti,ab.  
36 pharmacy.ti,ab.  
37 pharmacies.ti,ab.  
38 35 or 36 or 37 
39 27 and 34 and 38 
40 Remove duplicate from 39 
41 Export to Endnote and further remove of duplicate  
 485 
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Appendix 2. Risk of bias assessment tool  487 
Domain Low risk High risk Unclear 
1. Design bias (focus study 
question & design) 
• The study clearly described all of the following: 
• Targeted population  
• The intervention 
• The comparator 
• Outcomes measured 
• The study design is the best to answer the question, 
e.g. RCT for intervention  
• The study addressed the intended research question 
The study is not fulfilling any of these 
criteria  
Insufficient information to permit 
judgment of ‘Low risk’ or ‘High 
risk’ 
2. Selection bias (external and 
internal variations)  
• The study sample is representative of the intended 
population 
• There is nothing special about the sample with any 
potential to effect intervention or outcomes 
• All patients were included/ excluded as per the stated 
inclusion and exclusion criteria 
• The study groups are comparable at baseline 
The study is not fulfilling any of these 
criteria  
Insufficient information to permit 
judgment of ‘Low risk’ or ‘High 
risk’
1
 
3. Selection bias (randomisation) The investigators describe a random component in the 
sequence generation process 
2
 
The description of the sequence 
generation involve some systematic but 
non- random approach 
3
 
Insufficient information permit 
judgment of ‘Low risk’ or ‘High 
risk’ 
4. Selection bias (allocation 
concealment) 
Participants and investigators enrolling participants could 
not foresee the study group assignment 
4
 
Participants and investigators enrolling 
participants could possibly foresee the 
study group assignments 
5
 
Insufficient information permit 
judgment of ‘Low risk’ or ‘High 
risk’ 
  488 
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Domain Low risk High risk Unclear 
5. Performance bias (Standardised 
intervention delivery) 
The investigators used a standardised process which 
followed by all the service providers delivering the 
intervention 
6
 
The process of intervention delivery 
was not standardised  
Insufficient information to permit 
judgment of ‘Low risk’ or ‘High 
risk’ 
6. Performance bias (Standardised 
outcome measurement) 
The investigators used a standardised process which 
followed by all investigators recording and measuring t 
outcomes
7
 
The process for recording 
/measuring outcomes was not 
standardised 
Insufficient information to permit 
judgment of “‘Low risk’ or ‘High 
risk’ 
7. Detection bias (Blindness of the 
outcomes) 
• Blinding of outcome assessment ensured, and 
unlikely it was broken. 
• No blinding of the outcome assessment, but this 
unlikely to influence outcome assessment 
Outcomes measurement was not 
blind 
8
 
Insufficient information to permit 
judgement of ‘Low risk’ or ‘High 
risk’ 
8. Incomplete outcome data  • No missing outcome data and all study participants 
accounting for at conclusion 
9
  
• All pre-specified (primary and secondary) outcomes 
have been reported  
• The reported outcomes are appropriate to answer 
the study question 
The study is not fulfilling any of 
these criteria  
Insufficient information to permit 
judgement of ‘Low risk’ or ‘High 
risk’ 
9. Adequacy of study power 
(appropriate Statistical analysis)  
• The study used appropriate/justifiable statistical 
testing 
• Power calculation or sample size calculation was 
performed 
• Results do not match up or add up but with no 
major concern 
The study is not fulfilling any of 
these these criteria 
Insufficient information to permit 
judgement of ‘Low risk’ or ‘High 
risk’ 
 489 
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Explanatory notes: 491 
1. For example, groups were reported comparable but with no evidence to support this or groups reported different but no way of knowing if this is significant 492 
2. For example referring to a random number table, using a computer random number generator, coin tossing, shuffling cards or envelopes, throwing dice or drawing of 493 
lots 494 
3. For example generating sequence by odd or even date of birth, sequence generated by some rule based on date (or day) of admission, sequence generated by some 495 
rule based on hospital or clinic record number or other non- random approaches such as allocation by judgment of the clinician, the preference of the participant, on 496 
the results of a laboratory test or a series of tests or the availability of the intervention. 497 
4. For example the study allocation was concealed by central allocation (including telephone, web-based and pharmacy – controlled randomisation), sequentially 498 
numbered drug containers of identical appearance or sequentially numbered, opaque, sealed envelopes 499 
5. For example the study allocation based on using open random allocation schedule (e.g a list of random numbers), assignment envelopes were used without appropriate 500 
safeguards (e.g. if envelopes were unsealed or nonopaque or not sequentially numbered, alternation or rotation, date of birth, case recorded number or any other 501 
explicitly unconcealed procedure. 502 
6. For example the investigator used a standardised form or checklist or undertook a training  503 
7. I.e. the investigators used a structured review of medical chart, independent and double identification of medication discrepancies and demonstrate satisfactory 504 
agreement between the intervention assessors  505 
8. Detection bias criteria related to blinding of outcomes is considered of importance in assessing the measurement of medication discrepancies and their clinical 506 
significance. However, blinding of outcome assessors not particularly relevant to the end-points of hospital revisits or deaths and therefore it was assessed whether 507 
studies confirmed outcome data by using a subjective standardised reporting system such as hospital data or self-report data.   508 
9. I.e. attrition rate is similar between study groups, the study follow up is complete, patients were analysed as allocated at the study commencement, reasons for 509 
missing outcome data unlikely to be related to true outcome , missing outcome data balanced in numbers across intervention groups, with similar reasons for missing 510 
data across groups. In case of dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically 511 
relevant impact on the intervention effect estimate. For continuous outcome data, plausible effect size (difference in means or standardized difference in means) 512 
among missing outcomes not enough to have a clinically relevant impact on observed effect size and missing data have been imputed using appropriate methods. 513 
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Box 1. Composites of MR practice across a selection of excluded articles. 
  Admission MR Discharge MR 
Author, year 
 
country Collection of 
medicine 
history 
Clarification drug 
allergy 
Comparing  
collected 
information with 
inpatient chart 
Comparing 
inpatient with 
discharge charts 
Pharmacist 
intervene to resolve 
discrepancy 
Documenting 
changes  and 
communicate to 
next provider 
George et al., 20111 Australia       
Schnipper et al., 2009 2  USA       
Cohen et al., 2008 3 USA       
Abuyassin et al., 20114  Saudi 
Arabia 
      
Winter et al., 2010 5 Belgium       
Marino et al., 2010 6 US       
Steurbaut et al., 2010 7 Belgium 
      
Lisby et al., 2010 8 Denmark 
      
Green et al., 2010 9  UK       
Coffey et al., 2010 10 Canada       
Brownlie et al., 201411 UK       
Conklin et al., 201412* USA       
*involved follow calls within 72 hours of discharge 
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Box 2. Characteristics of patients in the studies reviewed.  
Authors, Year Demographics  Measurement Intervention  Control 
Andregg, 201431 Age  Mean (SD) 54.2 (16.4) 54.2 (17.1) 
 
Gender (male) N (%) 832 (50.4%) 878 (52.8%) 
 
No. of medication 
Admission  
Discharge  
New at discharge  
Mean (SD) 
 
 
11.8 (8.0) 
12.4 (7.0) 
3.8 (3.1) 
 
11.2 (7.8) 
12.2 (7.2) 
3.4 (2.8) 
 
Type of admission 
(planned) 
N (%) No details No details 
Brookes, 200025 
    
Age  Mean (Range) 75 (60-92) - 
Gender (male) N (%) No details No details 
 No. of medication Mean (Range) 8.0 (4-14) - 
 Type of admission 
(planned) 
N (%) No details No details 
Hellstrom,2011 34 Age  Mean (SD) 83.0 (7.0) 
 
81.8 (7.4) 
 Gender (male) N (%) 49 (45%) 50 (49.4%) 
 
 
No. of medications* Mean (IQ) 8 (5-11) 7 (5-11) 
Type of admission 
(planned) 
N (%) No details No details 
Hick, 2001 24 Age  Mean (SD) 67.4 (15.5)  63.0 (16.1) 
 Gender (male) N (%) 21(42.0%) 26 (52.0%) 
 No. of medications 
 
Admission * 
Discharge 
Mean (SD) 
 
 
 
2.78 (2.31) 
4.36 (2.51) 
 
 
2.52 (2.58) 
3.60 (3.0) 
 Type of admission 
(planned) 
N (%) 100%  100%  
Israel, 2013 30 Age  Mean (SD) No details No details 
 
Gender (male) N (%) 112 (45.7) 133 (54.3) 
 
No. of medication Mean (SD) 
 
No details No details 
 Type of admission 
(planned) 
N (%) No details No details 
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Continued  
Box 2. Characteristics of patients in the studies reviewed. 
Authors, Year Demographics  Measurement Intervention  Control 
Karapinar-Carkit, 
2012 35 
Age  Mean (SD) 65 (17) - 
 Gender (male) N (%) 131 (50%) - 
 No. of medications 
Admission  
Discharge  
Mean (SD) 
 
 
6.6 (3.8) 
9.1 (4.7) 
 
- 
- 
 Type of admission 
(planned) 
N (%) 35 (13%) - 
Kramer 2007 28 Gender (male) N (%) 74(51.0%) 69 (52.0%) 
 No. of medications Mean (SD) 8.3 (5.2) 6.0 (4.0) 
 Type of admission 
(planned) 
N (%) No details No details 
Makowsky, 2009 
27
  
 
Age  Mean (SD) 74.9 (13.9) 73.2 (14.7) 
Gender (male) N (%) 104 (47.1%) 102 (44.2%) 
No. of medications Mean (SD) No details No details 
 
Type of admission 
(planned) 
N (%) No details No details 
Perennes, 2012 33 
 
Age  Mean (SD) 78 (7.4) 
 
- 
Gender (male) N (%) 20 (31.2%) - 
No. of medications Mean (SD) 
 
7 (2.9)* 
 
- 
 
 Type of admission 
(planned) 
N (%) 46 (75%) - 
Rabi and Dahdal, 2007 
36
 
Age  Mean (SD) No details No details 
 Gender (male) N (%) No details No details 
 No. of medications**  Mean (SD) No details No details 
 Type of admission 
(planned) 
N (%) No details No details 
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Continued  
Box  2. Characteristics of patients in the studies reviewed. 
Authors, Year Demographics  Measurement Intervention  Control 
Scullin, 2007 26 
 
Age  Mean (SD) 70.3 (13.8)  69.9 (4.8) 
Gender (male) N (%) 167 (45.0%) 
 
192(49.0% 
No. of medications Mean (SD) No details No details 
Type of admission 
(planned) 
N (%) 0% 0% 
Stowasser, 2002 32 Age  Mean (SD) 67.4 (13.0) 65.6 (14.0) 
 Gender (male) N (%) 63(56.0%) 
 
69 (54.0%) 
 No. of medications 
Admission  
Discharge  
Mean (SD) 
 
 
7 (3.7) 
7.6 (3.5) 
 
7.2 (3.6)  
7.6 (3.8) 
Vira, 2006 29 Age  Mean (SD) 56.0 (24.0) - 
 Gender (male) N (%) 30 (50%) - 
 No. of medications 
Admission 
Mean (SD) 
 
3.6 (3.5) - 
 
Type of admission 
(planned) 
N (%)   13 (22%) - 
** Regular medicines only  
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Box 3. Time to implement medication reconciliation, by study reviewed. 
Author, Year Measure  Time per patients  
Hick, 2001 24 Mean  Medication history extra 5 minutes. Range (4 to 6) minutes, this equates 
to approximately 22.5 hours/month for an average caseload of 270 
patients. 
 The mean additional time commitment per patient was 11.5 minutes, 
which for an average caseload of 270 patients per month is equivalent to 
approximately 52 hours of the pharmacist’s time.  
Karapinar-Carkit,. 
2012 35 
Mean (SD) Total 62.7 (14.6) minuets  
 Admission and discharge medication reconciliation 32.9 (6.6) minutes  
 Patient counselling 26.6 (9.8) minutes  
 Transfer of medication information (including adjustments in final 
discharge prescriptions 3.3 (2.8) minutes  
Kramer, 2007 28 Mean (S.D)  Time required for nurses to enter allergies in the computer 
- Nurse time; Before vs. after MR intervention: 69.1 ± 98 vs.141.1 ± 238.8, 
p = 0.0315 
- Pharmacist time; Before vs. after MR intervention : 112.9 ± 70 minutes 
vs.64.1 ±38.7 minutes, p < 0.000 
 Time required to initiate the admission medication history after 
receiving trigger notification: 18.8 ± 20.2 minutes (range, 1–140 
minutes) 
 Time required to completed the admission medication history 12.9 ± 
9.34 minutes  
 Time required to clarify medications 1.18 ± 5.84 minutes  
 Time required to perform interventions 1.4 ± 2.25 minutes.  
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Table 3. Time to implement medication reconciliation, by study reviewed. 
Author, Year Measure  Time per patients  
Perennes, 2012 33 Mean (range) Total time 46 minutes 
 Patient interview or family member 16 (5-40) minutes  
 Obtain medication information from patient notes and GP letter 12 (5-
15) minutes 
 Obtain faxed copy of the medication dispensed by the community 
pharmacies 21 (10-45) minutes 
Rabi and Dahda, 
2007 36 
Mean   15 minutes for admission interview 
 10 minutes for discharge counselling including list of discharge 
medications prepared by study pharmacist and given to patient 
Vira T et al. 2006 29 Median (IQR)  Admission reconciliation 15 minutes (IQR 10–21).  
 Time required for discharge reconciliation was not record 
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Highlights  
• Transition of patients care between settings presents an increased opportunity 
for errors and preventable morbidity. 
• Medicine reconciliation is proposed as a solution for deficits at the health 
interface  
• Exploring the existing evidence to identify the features of MR practice and the 
resources necessary to deliver MR is warranted.  
 
• The lack of evidence precluded addressing the effects and costs of MR.  
 
• The composite of optimum MR practice is not widely standardised and requires 
discussion among health professions and key organizations. 
